Dihydrotestosterone (DHT)

Name: Dihydrotestosterone (DHT)
Brand: Selleck Chemicals
SKU: S4757
Rating: 5 (5 reviews)

For research use only.

Catalog No.S4757 Synonyms: androstanolone, stanolone, 5α-DHT

5 publications

Dihydrotestosterone (DHT) Chemical Structure

CAS No. 521-18-6

Dihydrotestosterone (DHT, androstanolone, stanolone, 5α-DHT) is an endogenous androgen sex steroid and hormone and a potent agonist of the androgen receptor with 2-3-fold greater androgen receptor affinity than testosterone and 10-fold higher potency of inducing androgen receptor signaling.

Selleck's Dihydrotestosterone (DHT) has been cited by 5 publications

Hum Reprod, 2020, 6 pii: deaa077

PubMed: 32372097 ( click the link to review the publication )

Prostate, 2020, 80(9):674-686

PubMed: 32294305 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 21;526(1):267-272

PubMed: 32209261 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:9821-9837

PubMed: 33061460 ( click the link to review the publication )

Circulation, 2019, 140(13):1070-1080

PubMed: 31378084 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Androgen Receptor Inhibitors

Biological Activity

Description

Targets

Androgen Receptor ^[1]
()

In vitro

In AR-positive bladder cancer UMUC3 and TCC-SUP cells, dihydrotestosterone (DHT) increased the expression of EGFR and ERBB2 both in mRNA and in protein levels. DHT additionally upregulated the levels of phosphorylation of EGFR (pEGFR) and its downstream proteins AKT (pAKT) and ERK1/2 (pERK), induced by EGF treatment, in AR-positive cells^[1].

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
CV-1 cell	NEHyVXlHfW6ldHnvckBie3OjeR?=			MmjSRYdwdmm\|dHnjJIFkfGm4aYT5JEhGSzVyKTDh[4FqdnO2IHj1cYFvKGGwZILv[4VvKHKnY3XweI9zKGW6cILld5Nm\CCrbjDDWk0yKGOnbHysJGVEPTB;MD6wNFYh\|ryP	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86QDdzNUO0K\|46QDdzNUO0QE9iRg>?
MDA-MB-453 cell	NWrLbYtPTnWwY4Tpc44h[XO\|YYm=			M{HlWWRqe3CuYXPlcYVvfCCxZjDbN2heTEiWIH\yc40hcHWvYX6gZY5lem:pZX6gdoVk\XC2b4Kg[ZhxemW\|c3XkJIlvKE2GQT3NRk01PTNiY3XscJMh[nlid3jvcIUh[2WubDDy[YNmeHSxcjDibY5lcW6pIHHzd4F6NCCNaU2wMlAxODJizszN	NFXxTG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{CzOFEyPyd-MUewN\|QyOTd:L3G+
HepG2 cell	NXv2bYxFTnWwY4Tpc44h[XO\|YYm=			MYnBZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKGGwZILv[4VvKHKnY3XweI9zKGW6cILld5Nm\CCrbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[WO2aY\heIlwdixiSVO1NF0xNjBzOEKg{txO	M3vJblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUS5PFY3Lz5zN{G0PVg3PjxxYU6=
MDA453 cell	M1PDdGZ2dmO2aX;uJIF{e2G7			MVrEbZNxdGGlZX3lcpQhd2ZiW{PIYWRJXCCocn;tJIh2dWGwIFHSJIlvKE2GQUS1N{Bk\WyuczygT4k:OC5yMEOg{txO	MnfWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzOEGxOFEoRjF5MUixNVQyRC:jPh?=
mouse C2C12 cell	NWLidoZmTnWwY4Tpc44h[XO\|YYm=			NXTWfFdCSWexbnnzeEBi[3Srdnn0fUBifCC{YYSgRXIhfHKjboPm[YN1\WRiaX6gcY92e2ViQ{LDNVIh[2WubIOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiC2cnHud4FkfGm4YYTpc44h[XO\|YYmsJGVEPTB;MD6wNlgh\|ryP	NUfFbIVERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexPFEyPDFpPkG3NVgyOTRzPD;hQi=>
monkey COS7 cell	MVLGeY5kfGmxbjDhd5NigQ>?			NWT3NIhwSmmwZHnu[{Bi\m[rbnn0fUB1dyCqdX3hckBidmS{b3flckBz\WOncITvdkBmgHC{ZYPz[YQhcW5ibX;ub4V6KEORU{egZ4VtdHNiYomge4hwdGViY3XscEBjcW6maX7nJIF{e2G7LDDLbV0xNjByMEKg{txO	MkXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2NEK5NVIoRjF6NESyPVEzRC:jPh?=
CHO cell	NGDabnVHfW6ldHnvckBie3OjeR?=			MX7B[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGTHVlUh\XiycnXzd4VlKGmwIFPIU{Bk\WyuczDifUBtfWOrZnXyZZNmKGG\|c3H5MEBGSzVyPUSuOFkh\|ryP	MnHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|MEeyPVQoRjF6M{C3Nlk1RC:jPh?=
COS7 cell	NXfOdpZiTnWwY4Tpc44h[XO\|YYm=			MmfqRYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDXO\|QySyCvdYThcpQh\XiycnXzd4VlKGmwIFPPV\|ch[2WubIOgZZN{\XO\|ZXSgZZMhdHWlaX\ldoF{\SCjY4Tpeol1gSCjZoTldkAzPCCqcoOgZpkhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjBzMjFOwG0>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB7NEK3PUc,OjJyOUSyO\|k9N2F-
COS7 cell	MlHQSpVv[3Srb36gZZN{[Xl?			MVrB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IGS4O\|dCKG23dHHueEBmgHC{ZYPz[YQhcW5iQ1;TO{Bk\WyuczDhd5Nme3OnZDDhd{BtfWOrZnXyZZNmKGGldHn2bZR6KGGodHXyJFI1KGi{czDifUBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvODF3IN88US=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB7NEK3PUc,OjJyOUSyO\|k9N2F-
COS7 cell	NVftcHc3TnWwY4Tpc44h[XO\|YYm=			MUPB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEV1N5IHPlcIx{KGG\|c3Xzd4VlKGG\|IHz1Z4ln\XKjc3WgZYN1cX[rdImgZYZ1\XJiMkSgbJJ{KGK7IILldI9zfGW{IHflcoUh[XO\|YYmsJGVEPTB;MD6wNFYzKM7:TR?=	NXjhOGk5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwPVQzPzlpPkKyNFk1Ojd7PD;hQi=>
LNCaP-hr cell	NGG3R5JHfW6ldHnvckBie3OjeR?=		Ml3QN{Bl[Xm\|	Mnj4RYdwdmm\|dDDhZ5Rqfmm2eTDheEBCdmS{b3flckBz\WOncITvdkBVQDd5QTDteZRidnRiaX6gbJVu[W5iTF7DZXAucHJiY3XscJMh[XO\|ZYPz[YQh[XNicILvd5RifGVic4DlZ4lncWNiYX70bYdmdiC\|ZXPy[ZRqd25ibXXhd5Vz\WRiYX\0[ZIhOyCmYYnzJIJ6KGWweont[U1qdW23bn;hd5NigSxiRVO1NF0xNjBzNTFOwG0>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF7OUS3O{c,OjNzOUm0O\|c9N2F-
LNCaP-hr cell	M37UbGZ2dmO2aX;uJIF{e2G7		MX:zJIRigXN?	NHP3ZXFC\2:waYP0JIFkfGm4aYT5JIF1KHerbHSgeJlx\SCDbnTyc4dmdiC{ZXPldJRweiCrbjDoeY1idiCOTlPhVE1peiClZXzsd{Bie3Onc4Pl[EBieyCycn;zeIF1\SC\|cHXjbYZq[yCjboTp[4VvKHOnY4LleIlwdiCvZXHzeZJm\CCjZoTldkA{KGSjeYOgZpkh\W68eX3lMYludXWwb3Hzd4F6NCCHQ{WwQVAvODB4MjFOwG0>	NH3Gd\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G5PVQ4Pyd-MkOxPVk1Pzd:L3G+
HEK293 cell	M2fyZmZ2dmO2aX;uJIF{e2G7			M4r4TmFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gZY5lem:pZX6gdoVk\XC2b4Kg[ZhxemW\|c3XkJIlvKEiHS{K5N{Bk\WyuczDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC5zODDuUS=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyNU[4PEc,OjV\|MEW2PFg9N2F-
COS	MXrGeY5kfGmxbjDhd5NigQ>?			NVvoSlZISmmwZHnu[{Bi\m[rbnn0fUBi\2GrboP0JGFv\HKxZ3XuJJJm[2WydH;yJIV5eHKnc4Pl[EBEV1NiY3XscJMtKEurIE2gNE4xODJizszNMi=>	M2HXfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzl6N{G1N\|QoRjl6N{G1N\|Q9N2F-
COS-1	NXXUSIlGTnWwY4Tpc44h[XO\|YYm=			NYO1N4lISmmwZHnu[{Bi\m[rbnn0fUBnd3JiaIXtZY4hSW6mcn;n[Y4hemWlZYD0c5Ih\XiycnXzd4VlKGmwIFPPV{0yKGOnbHzzMEBMcSB;IECuNFA{KM7:TT6=	Mli5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQTl{NUeyOUc,QTl{NUeyOVww[T5?
CV-1	MXvGeY5kfGmxbjDhd5NigQ>?			MYPB[49vcXO2IHHjeIl3cXS7IHHnZYlve3RiSIXtZY4hSW6mcn;n[Y4hemWlZYD0c5Ih\XiycnXzd4VlKGmwIFPWMVEh[2WubIOsJGVEPTBiPTCwMlAxPSEQvF2u	MorqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQTl{NUeyOUc,QTl{NUeyOVww[T5?
COS	NWrZVo5{TnWwY4Tpc44h[XO\|YYm=			M3LUc2lvKH[rdILvJIJqdmSrbnegZYZncW6rdImgZZQhcHWvYX6gZY5lem:pZX6gdoVk\XC2b4KgeJJidnOoZXP0[YQhcW62bzDDU3Mh[2WubIOuMEBKSzVyIE2gNE4xODRizszNMi=>	NWK1ToRMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUCyN\|A3OjhpPkGwNlMxPjJ6PD;hQi=>
CV-1	MXTGeY5kfGmxbjDhd5NigQ>?			MX\JckB3cXS{bzDh[49vcXO2aXOgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCjbnTyc4dmdiC{ZXPldJRweiC3c3nu[{Bkd3S{YX7z[oVkfGmxbjDhd5NigSCrbjDDWk0yKGOnbHzzMkwhTUN3MDC9JFAvODB4IN88UU4>	M4rnfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyMkOwOlI5Lz5zMEKzNFYzQDxxYU6=
CV-1	NFfiSW1HfW6ldHnvckBie3OjeR?=			NXzKRm9qSWexbnnzeEBi[3Srdnn0fUB1dyC2aHWgbJVu[W5iYX7kdo9o\W5icnXj[ZB1d3JiKHjBVkkhcW5iQ2[tNUBk\WyuczygSWM2OCB;IECuNFA3KM7:TT6=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODN2ME[yOEc,OTB\|NEC2NlQ9N2F-
CV1	NXLLd2l5TnWwY4Tpc44h[XO\|YYm=			MYXB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHnuJGNXOSClZXzsd{Bu\WG\|dYLl[EBieyC\|dHnteYxifGmxbjDv[kBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZYN1cX[rdImgZpkh[2:2cnHud4Zm[3Srb36gZZN{[XluIFXDOVAhRSByLkCwOVEh\|ryPLh?=	NIXwWpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{CzOFEyPyd-MUewN\|QyOTd:L3G+
CV1	NWrpeohrTnWwY4Tpc44h[XO\|YYm=			MkTxRolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO\|ZXSgbY4hS1ZzIHPlcIx{NCCNaTC9JFAvODByMjFOwG0v	M1jYeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MkW3PFM5Lz5zN{K1O\|g{QDxxYU6=
CV1	MmniSpVv[3Srb36gZZN{[Xl?			Mmj5RYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO\|ZXSgbY4hS1ZzIHPlcIx{NCCHQ{WwJF0hOC5yMEWxJO69VS5?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzJ3N{izPEc,OTd{NUe4N\|g9N2F-
MDA-MB-453	NXnHTlF1TnWwY4Tpc44h[XO\|YYm=			NXPPUJhOTGm\|cHzhZ4Vu\W62IH;mJHs{UF2GSGSg[pJwdSCqdX3hckBCWiCneIDy[ZN{\WRiaX6gUWRCNU2ELUS1N{Bk\WyuczygT4khRSByLkCwNFMh\|ryPLh?=	NV7ybmZlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0N\|kyOTJpPkG3OFM6OTF{PD;hQi=>
CV1	MmLSSpVv[3Srb36gZZN{[Xl?			MYXB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEXjFiY3XscJMh[nlidILhcpNkemmydHnvcoFtKGGldHn2ZZRqd25iYYPzZZktKEWFNUCgQUAxNjByNUeg{txONg>?	M2S3ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEO5NVEzLz5zN{SzPVEyOjxxYU6=
CV1	MV7GeY5kfGmxbjDhd5NigQ>?			NV\KbGlpSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBidmS{b3flckBz\WOncITvdkBmgHC{ZYPz[YQhcW5iQ2[xJINmdGy\|IHL5JJRz[W6\|Y4LpdJRqd26jbDDhZ5RqfmG2aX;uJIF{e2G7LDDFR\|UxKD1iMD6wNFU4KM7:TT6=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzdyM{mzPEc,OTd5MEO5N\|g9N2F-
MDA-MB-453	M3jy[GZ2dmO2aX;uJIF{e2G7			M1Xw[GRqe3CuYXPlcYVvfCCxZjDbN2heTEiWIH\yc40hcHWvYX6gRY5lem:pZX6gdoVk\XC2b4KgbY4hcHWvYX6gUWRCNU2ELUS1N{Bk\WyuczygT4khRSByLkCwNFkh\|ryPLh?=	NFzjbW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOESwNFQ6QSd-MUi0NFA1QTl:L3G+
CV1	M4ixNWZ2dmO2aX;uJIF{e2G7			MXHB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHnuJGNXOSClZXzsd{BjgSC2cnHud4NzcXC2aX;uZYwh[WO2aY\heIlwdiCjc4PhfUwhTUN3MDC9JFAvODB3NzFOwG0v	MnOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2MEC0PVkoRjF6NECwOFk6RC:jPh?=
Saos2	M1;jRWZ2dmO2aX;uJIF{e2G7			M{LWc2FkfGm4aYT5JIF1KGGwZILv[4VvKHKnY3XweI9zKGmwIHj1cYFvKFOjb4OyJINmdGy\|IHHzd4V{e2WmIHHzJGlNPiC{ZYDy[ZN{cW:wLDDJR\|UxKD1iMD6wNFAxPSEQvF2u	MnzQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2NEK5NVIoRjF6NESyPVEzRC:jPh?=
CV1	NF\VdItHfW6ldHnvckBie3OjeR?=			NYLwO293SWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBidmS{b3flckBz\WOncITvdkBi\nKrY3HuJIdz\WWwIH3vcotmgSCFVkGgZ4VtdHNiYomgZ491emGwc3\lZ5Rqd25iYYPzZZktKEWFNUCgQUAxNjByNUGg{txONg>?	MnfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2NEK5NVIoRjF6NESyPVEzRC:jPh?=
MDA-kb2	NFjxS3pHfW6ldHnvckBie3OjeR?=			NF7XNFhC\2:waYP0JIFkfGm4aYT5JIF1KGGwZILv[4VvKHKnY3XweI9zKGmwIHj1cYFvKE2GQT3rZlIh[2WubIOgZZN{\XO\|ZXSgZZMhe3SrbYXsZZRqd25ib3[gcJVkcW[ncnHz[UBi[3Srdnn0fUBjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGVEOTVyIE2gNE4xODB3IN88UU4>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTV7MkK0OUc,OTl3OUKyOFU9N2F-
MDA-kb2	NHLvTnBHfW6ldHnvckBie3OjeR?=			MX;B[49vcXO2IHHjeIl3cXS7IHH0JIdtfWOxY3;yeIlkd2mmIILlZ4VxfG:{IHnuJIh2dWGwIF3ERU1s[jJiY3XscJMh[XO\|ZYPz[YQh[XNic4TpcZVt[XSrb36gc4YhdHWlaX\ldoF{\SCjY4Tpeol1gSCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFMUWwJF0hOC5yMEC1JO69VS5?	NITmS\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUW5NlI1PSd-MUm1PVIzPDV:L3G+
MDA-MB-453	MUTGeY5kfGmxbjDhd5NigQ>?			NUW5[pVMTGm\|cHzhZ4Vu\W62IH;mJHs{UF2vZYTofYx1emmnbn;sc45mKG[{b32gZY5lem:pZX6gdoVk\XC2b4KgbY4hcHWvYX6gUWRCNU2ELUS1N{Bk\WyuczygTWM2OCB;IECuNFAyKM7:TT6=	M1zCXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NkC2PFcxLz5zOU[wOlg4ODxxYU6=
MDA-MB-453	M2rCTmZ2dmO2aX;uJIF{e2G7			MmfoRYdwdmm\|dDDhZ5Rqfmm2eTDheEBidmS{b3flckBz\WOncITvdkBqdiCqdX3hckBOTEFvTVKtOFU{KGOnbHzzJJRz[W6\|ZnXjeIVlKHerdHigUW1VXi2OVVOgZZN{\XO\|ZXSgZZMhcW6mdXP0bY9vKG:oIF3NWHYuVFSUL4Dyc41wfGW{IHzpcotm\CCOVVOg[4Vv\SCkeTDseYNq\mW{YYPlJJRz[W6\|YXP0bZZifGmxbjDhd5NigSxiRVO1NEA:KDBwMECyJO69VS5?	NUXSUHJwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm2NFY5PzBpPkG5OlA3QDdyPD;hQi=>
NIH3T3	NWj1T5RlTnWwY4Tpc44h[XO\|YYm=			NXe0RZNjSWexbnnzeEBi[3Srdnn0fUBifCCjbnTyc4dmdiC{ZXPldJRweiCOQlSgWFg4P0FibYX0ZY51KGmwIH3veZNmKE6LSEPUN{Bk\WyuczD0doFve2mnboTsfUB1emGwc3\lZ5Rm\CC5aYToJIJmfGFvZ3HsZYN1d3OrZHHz[UBz\XCxcoTldkBo\W6nIHHzd4V{e2WmIHHzJINmdGy3bHHyJJRz[W6\|Zn;ycYF1cW:wIHL5JHIuW0GWIHHzd4F6NCCHQ{WwJF0hOC5yMEGyOVkh\|ryPLh?=	NEjxfWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUi1OlkzOSd-MUm4OVY6OjF:L3G+
NIH3T3	MX3GeY5kfGmxbjDhd5NigQ>?			MnvsRYdwdmm\|dDDhZ5Rqfmm2eTDheEBidmS{b3flckBz\WOncITvdkBqdiCvb4Xz[UBPUUh\|VEOgZ4VtdHNidILhcpNq\W62bImgeJJidnOoZXP0[YQhf2m2aDDi[ZRiNWejbHHjeI9{cWSjc3WgdoVxd3K2ZYKg[4Vv\SCjc4Pld5Nm\CCjczDj[YxtfWyjcjD0doFve2[xcn3heIlwdiCkeTDSMXNCXCCjc4PhfUwhTUN3MDC9JFAvODB\|OUixJO69VS5?	NVXDcHBZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4OVY6OjFpPkG5PFU3QTJzPD;hQi=>
COS7	MXrGeY5kfGmxbjDhd5NigQ>?			MVLB[49vcXO2IHHjeIl3cXS7IHH0JIFv\HKxZ3XuJJJm[2WydH;yJIxq\2GwZDDibY5lcW6pIHTvcYFqdiCneIDy[ZN{\WRiaX6gZYZzcWOjbjDndoVmdiCvb37r[ZkhS0:VNzDj[YxteyClbz30doFve2[nY4Tl[EB4cXSqIFfhcFQuTEKGIHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDBwMEKg{txONg>?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh4M{C4N{c,OTl6NkOwPFM9N2F-
Freestyle293F	NFTmOHNHfW6ldHnvckBie3OjeR?=		NYW2NlNIOyCqcoO=	NX7oVYZ1TGm\|cHzhZ4Vu\W62IH;mJHsyPy2jbIDoZU1u\XSqeXytN2heNW2rYn;s[ZJwdmViZoLvcUBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO\|ZXSgbY4hUEWNMkmzJIRmemm4ZXSgSpJm\VO2eXzlNlk{TiClZXzsd{Bi\nSncjCzJIhzeyxiSVO1NEA:KDBwMECyNUDPxE1w	MkTsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyOUSyO\|koRjJ{MEm0Nlc6RC:jPh?=
Freestyle293F	NX\WXYwyTnWwY4Tpc44h[XO\|YYm=		NEHMUWw{KGi{cx?=	NVTLZYQyTGm\|cHzhZ4Vu\W62IH;mJHsyPy2jbIDoZU1u\XSqeXytN2heNW2rYn;s[ZJwdmViZoLvcUBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDUPFc4SSCvdYThcpQh\XiycnXzd4VlKGmwIFjFT\|I6OyCmZYLpeoVlKE[{ZXXTeJlt\TJ7M1[gZ4VtdHNiYX\0[ZIhOyCqcoOsJGlEPTBiPTCwMlAxOjZizszNMi=>	NFKy[3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC5OFI4QSd-MkKwPVQzPzl:L3G+
HeLa	NYHhUnVITnWwY4Tpc44h[XO\|YYm=			M3mxN3Rz[W6\|YXP0bZZifGmxbjDv[kBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjD0doFve2[nY4Tl[EBqdiCqdX3hckBJ\UyjIHPlcIx{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhSWO2aY\peJkhRSByLkCwPEDPxE1w	NUO0U2dQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4PVc3OTFpPkKyPFk4PjFzPD;hQi=>
HeLa	M1e4V2Z2dmO2aX;uJIF{e2G7			NVfZdIRWWGG{dHnhcEBi\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCKZVzhJINmdGy\|IHPvMYV5eHKnc4PpcochSVKHIHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDiZZNm\CC2cnHud4FkfGm4YYTpc44h[XO\|YYmsJGFkfGm4aYT5JF0hOC5yMEig{txONg>?	Ml\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NUe5OFcoRjJ{OUW3PVQ4RC:jPh?=
Freestyle293F	NW\XNYlpTnWwY4Tpc44h[XO\|YYm=			MYHJcohq[mm2aX;uJI9nKHerbHSgeJlx\SCDbnTyc4dmdiC{ZXPldJRweiBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDGdoVme3S7bHWyPVNHKGOnbHzzMEBKSzVyIE2gNE4xODJzIN88UU4>	M4LjTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUm5OFc4Lz5{M{G5PVQ4PzxxYU6=
Freestyle293F	M3ixOGZ2dmO2aX;uJIF{e2G7			M3PTPWlvcGmkaYTpc44hd2ZiQX7kdo9o\W5icnXj[ZB1d3JiVEi3O2EhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKE[{ZXXzeJlt\TJ7M1[gZ4VtdHNuIFnDOVAhRSByLkCwNlYh\|ryPLh?=	NHLlOY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G5PVQ4Pyd-MkOxPVk1Pzd:L3G+
COS7	MXzGeY5kfGmxbjDhd5NigQ>?		NEiyNGkzKGi{cx?=	NW\wZllqTGm\|cHzhZ4Vu\W62IH;mJHs{UF1iXUXhcJBp[S2GSGSg[pJwdSCvb4Xz[UBidmS{b3flckBz\WOncITvdkBmgHC{ZYPz[YQhcW5ibX;ub4V6KEORU{egZ4VtdHNiYX\0[ZIhOiCqcoOgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzDhcoFtgXOrczygTWM2OCB;IECuNFAyKM7:TT6=	M2HkPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUK3PFE3Lz5{M{WyO\|gyPjxxYU6=
C2C12	NInMTolHfW6ldHnvckBie3OjeR?=		MYi1JIRigXN?	M{nNU2Fod26rc4SgZYN1cX[rdImgZZQh[W6mcn;n[Y4hemWlZYD0c5Ih\XiycnXzd4VlKGmwIH3veZNmKEN{Q{GyJINmdGy\|IHHzd4V{e2WmIHHzJI9{fGWxYnzhd5Qh\GmoZnXy[Y51cWG2aX;uJIFnfGW{IEWg[IF6eyxiRVO1NEA:KDBwMECwNFUh\|ryPLh?=	MlnTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyPVAoRjJ2OUCwNlkxRC:jPh?=
C2C12	M{fPT2Z2dmO2aX;uJIF{e2G7			M{DIW2Fod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gZY5lem:pZX6gdoVk\XC2b4Kg[ZhxemW\|c3XkJIlvKG2xdYPlJGMzSzF{IHPlcIx{KGK7IHHu[JJw\2WwLYPw[YNq\mmlIILld5BwdnOnIHXs[Y1mdnRvZILpeoVvKGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OCB;IECuNFAxOTNizszNMi=>	Ml\mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkG5OlQoRjJ3MUKxPVY1RC:jPh?=
COS7	MkDySpVv[3Srb36gZZN{[Xl?		NXqwdZB{OjRiaILz	Ml;lRYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDBVkBmgHC{ZYPz[YQhcW5iQX\ybYNidiCpcnXlckBud26tZYmgR29UPyClZXzsd{Bi\nSncjCyOEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwJF0hOC5yMEOg{txONg>?	NXG2cGpmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0OVQ5PDlpPkK4OFU1QDR7PD;hQi=>
Shionogi	NF\TOWpHfW6ldHnvckBie3OjeR?=	MnLjNVAheE1?		MXnJcoR2[3Srb36gc4YheHKxbHnm[ZJifGmxbjDv[kBud3W\|ZTDTbIlwdm:paTDj[YxteyCjdDCxNEBxVQ>?	M3fGU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5N{GxPFU2Lz5zN{exNVg2PTxxYU6=
MCF7	MXHGeY5kfGmxbjDhd5NigQ>?	NWTxT3VUOzBidV2=	NW\TWW1lOjRiaILz	MnzaRY51[WexbnnzeEBi[3Srdnn0fUBifCCDUjDpckBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDBVkBt\X[nbDDheEA{OCC3TTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nzJJJmdGG2aY\lJJRwKGOxboTyc4w>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjBzNEe1NUc,OjJyMUS3OVE9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Cyclin D1 / Cyclin D2 / Cyclin D3 / Cyclin E2 / Cyclin A1 / AR; PubMed: 26372468 PLoS One HPr-1AR cells were treated with 10 nM DHT or vehicle control for 24–48 hours (h), and immunoblot analysis of cell lysates reveals that cyclin D1 and D2 protein expression decreased substantially with DHT treatment compared to vehicle. p-CDK2 / CDK2 / CDK4 / CDK6 / CDKN1A / p-RB / RB ; PubMed: 26372468 PLoS One HPr-1AR cells were treated with 10 nM DHT or vehicle control for 24–48 hours (h). Immunoblot analysis of cell lysates reveals that CDK4 and CDK6 protein expression decreased and CDKN1A expression increased with DHT treatment compared to vehicle. CDK2 phosphorylation at threonine 160 (T160) decreased nearly 50% with androgen treatment at 24 and 48 hours, albeit not significantly, and total CDK2 protein expression remained unchanged. Relative to total RB expression, the levels of various phosphorylated forms of RB (S780 and S807/811) decreased over time with androgen treatment. p27 / p-p27 ; PubMed: 22139837 J Biol Chem CWR22Rv1 or CWR22R3 cells were stimulated with 10 nm DHT for 6 h, with the addition of MG132 during the last 2 h before harvesting. Proteins were then immunoblotted. AR / PP1 ; PubMed: 26636645 Oncotarget HeLa cells were transfected with Flag-PP1α and HA-AR and then incubated for overnight in androgen-depleted medium without or with androgen (10 nM of DHT) as indicated for blotting.	26372468 22139837 26636645
Immunofluorescence	FOXO1 / p27 ; PubMed: 22139837 J Biol Chem CWR22R3 cells cultured in medium with CDS serum were treated without/with DHT (10 nm) for 4 h. The cells were immunostained for FOXO1 and p27 and examined with a confocal microscope. AKT(S473) / PKCα(S657) ; PubMed: 22139837 J Biol Chem CWR22R3 cells cultured in medium with CDS serum were treated without/with 10 nm DHT (−/+ DHT) for 4 h. The cells were immunostained for AKT or PKCα phosphorylation and examined with a confocal microscope. Bars: 20 μm	22139837

In vivo

DHT-treated SOD1-G93A mice demonstrate ameliorated muscle atrophy and increased body weight, which is associated with stronger grip-strength. DHT treatment increases the expression of insulin-like growth factor-1 in muscle, which can exert myotrophic as well as neurotrophic effects through retrograde transport. DHT treatment attenuates neuromuscular junction denervation, and axonal and motoneuron loss. DHT-treated SOD1-G93A mice demonstrates improvement in motor behavior as assessed by rota-rod and gait analyses, and an increased lifespan^[2].

Protocol

Cell Research:

^[1]

- Collapse

Cell lines: Bladder cancer cells
Concentrations: 1 nM
Incubation Time: 24 h
Method:
Bladder cancer cells at a density of 50-60% confluence in 24-well plates are co-transfected with 250 ng of MMTV-luc reporter plasmid DNA and 2.5 ng of PRL-TK-luc plasmid DNA. After 6 h of transfection, the medium is replaced with another medium supplemented with charcoal-stripped FBS in the presence or absence of ligands (DHT, HF, or both) for 24 h. Cells were harvested, lysed, and assayed for luciferase activity.

(Only for Reference)

Animal Research:

^[2]

- Collapse

Animal Models: SOD1-G93A mutant mice with the congenic C57BL/6J background
Dosages: 5 mg
Administration: silastic implant
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	58 mg/mL (199.69 mM)
	Ethanol	58 mg/mL (199.69 mM)
	Water	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dihydrotestosterone (DHT) SDF

Molecular Weight	290.44
Formula	C₁₉H₃₀O₂
CAS No.	521-18-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	androstanolone, stanolone, 5α-DHT
Smiles	CC12CCC(=O)CC1CCC3C2CCC4(C3CCC4O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04032067	Not yet recruiting	Drug: GV1001 placebo\|Drug: Proscar placebo	Benign Prostatic Hyperplasia (BPH)	GemVax & Kael	August 28 2019	Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Androgen Receptor Signaling Pathway Map

Related Androgen Receptor Products

Darolutamide (ODM-201) ^New

Darolutamide (ODM-201, BAY-1841788) is a novel androgen receptor (AR) antagonist that blocks AR nuclear translocation with K_i of 11 nM. Phase 3.
Sacubitril/valsartan (LCZ696) ^New

Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.
Endoxifen HCl ^New

Endoxifen HCl, the active metabolite of Tamoxifen, ia a potent and selective estrogen receptor antagonist. Phase 2.
Enzalutamide (MDV3100)

Enzalutamide (MDV3100) is an androgen-receptor (AR) antagonist with IC50 of 36 nM in LNCaP cells. Enzalutamide is shown to increase autophagy.
Bicalutamide

Bicalutamide (ICI-176334) is an androgen receptor (AR) antagonist with IC50 of 0.16 μM in LNCaP/AR(cs)cell line. Bicalutamide promotes autophagy.
Apalutamide (ARN-509)

Apalutamide (ARN-509) is a selective and competitive androgen receptor inhibitor with IC50 of 16 nM in a cell-free assay, useful for prostate cancer treatment. Phase 3.
Dehydroepiandrosterone (DHEA)

Dehydroepiandrosterone is an important endogenous steroid hormone, which is an androgen receptor antagonist and an estrogen receptor agonist.
Galeterone

Galeterone (TOK-001) is a selective CYP17 inhibitor and androgen receptor (AR) antagonist with IC50 of 300 nM and 384 nM, respectively, and is a potent inhibitor of human prostate tumor growth. Phase 2.
Ostarine (GTx-024)

Ostarine (GTx-024, MK-2866) is a selective androgen receptor modulator (SARM) with K_i of 3.8 nM, and is tissue-selective for anabolic organs. Phase 3.

Features:The most potent and tissue-selective in vivo activity of SARMs to date, with favorable pharmacokinetic properties.
Flutamide

Flutamide (SCH-13521) is an antiandrogen drug, with its active metablolite binding at androgen receptor with K_i values of 55 nM, and primarily used to treat prostate cancer.

Choose Your Country or Region

By Signaling Pathways

By product type

Dihydrotestosterone (DHT)